U.S. market Closed. Opens in 16 hours 46 minutes

AGLE | Aeglea BioTherapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue2.33M18.74MN/AN/A3.89M5.21M4.63M6.08MN/A
Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/A
Gross Profit2.33M18.74MN/AN/A3.89MN/AN/AN/AN/A
Operating Expenses87.11M84.39M81.48M80.33M49.35M32.88M26.53M17.40MN/A
Selling, General & Admin28.53M27.32M21.84M15.73M12.63M10.07M8.39M5.95M2.07M
Research & Development58.58M57.07M59.64M64.60M36.72M22.82M18.14M11.45M6.83M
Other Operating Expenses-7.00K-122.00K-5.00K-63.00K-57.00KN/AN/AN/A-8.90M
Operating Income-84.78M-65.65M-81.48M-80.33M-45.46M-27.68M-21.91M-11.31M-8.90M
Other Expenses / Income830.00K-11.00K588.00K2.08M-57.00K440.00K208.00K20.00K-1.44M
Before Tax Income-83.95M-65.66M-80.89M-78.25M-44.35M-27.24M-21.70M-11.29M-10.35M
Income Tax Expenses-136.00K141.00K-593.00K-2.56M-57.00KN/AN/AN/AN/A
Net Income-83.81M-65.80M-80.30M-75.69M-44.35M-27.24M-21.70M-11.29M-10.35M
Interest Expenses837.00KN/AN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding3.37M2.63M2.13M1.28M832.90K15.13M9.79M6.82M6.82M
Diluted Shares Outstanding3.37M2.63M2.13M1.28M832.90K15.13M9.79M6.82M6.82M
EBITDA-84.78M-65.65M-80.48M-80.33M-44.05M-26.99M-21.57M-11.21M-7.44M
EBITDA Margin-3,640.23%-350.33%0.00%0.00%-1,133.10%-518.48%-465.99%-184.16%0.00%
EBIT-83.11M-65.66M-80.89M-78.25M-44.41M-27.24M-21.70M-11.29M-10.35M
EBIT Margin-3,568.66%-350.39%0.00%0.00%-1,142.10%-523.27%-468.84%-185.62%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙